Skip to content

Study · Ex vivo tissue · 2001

2 results

The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity.

Zozulya AA, Kost NV, Yu Sokolov O, Gabaeva MV, Grivennikov IA, Andreeva LN, Zolotarev YA, Ivanov SV, Andryushchenko AV, Myasoedov NF, Smulevich AB

Bulletin of experimental biology and medicine1 Apr 2001Cited by 8 (Europe PMC)

PMID11550013 (opens in a new tab)DOI10.1023/a:1017979514274 (opens in a new tab)PepBankPUB-11550013
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In plasma tests, Selank dose-dependently inhibited enzymatic hydrolysis of enkephalin (IC50 15 microM).

    In plain wordsIn lab tests with blood plasma, Selank slowed the breakdown of enkephalin, depending on the dose.

    Peptide
    Selank
    Outcome
    DecreaseInhibition of plasma enkephalin hydrolysis
    Study

    n: not reported in source

    plasma enkephalin hydrolysis
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    IC50
    15 microM
    plasma enkephalin hydrolysis

    Source sentences

    Summary
    Heptapeptide Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro), which attenuates behavioral anxiety reactions and does not cause side effects typical of most anxiolytics, dose-dependently inhibited enzymatic hydrolysis of plasma enkephalin (IC50 15 microM).
  2. 02LabEx vivo tissueActivity measurement

    In plasma tests, Selank was more potent than the peptidase inhibitors bacitracin and puromycin in inhibiting enkephalinases.

    In plain wordsIn lab tests, Selank blocked enkephalin-degrading enzymes more strongly than bacitracin and puromycin.

    Peptide
    Selank
    Outcome
    IncreaseEnkephalinase inhibition potency versus bacitracin and puromycin
    Study

    n: not reported in source

    plasma enkephalin hydrolysis
    Comparator
    Bacitracin and puromycin
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Selank was more potent than peptidase inhibitors bacitracin and puromycin in inhibiting enkephalinases.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.